353 related articles for article (PubMed ID: 21776573)
1. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty.
Iwamoto N; Inaba Y; Kobayashi N; Ishida T; Yukizawa Y; Saito T
J Bone Joint Surg Am; 2011 Jul; 93(13):1203-9. PubMed ID: 21776573
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.
Yukizawa Y; Inaba Y; Kobayashi N; Choe H; Kubota S; Saito T
J Arthroplasty; 2017 Jul; 32(7):2176-2180. PubMed ID: 28318867
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of mono or combined osteoporosis drug therapy against bone mineral density loss around femoral implants after total hip arthroplasty.
Iwamoto N; Inaba Y; Kobayashi N; Yukizawa Y; Ike H; Ishida T; Saito T
J Bone Miner Metab; 2014 Sep; 32(5):539-44. PubMed ID: 24233122
[TBL] [Abstract][Full Text] [Related]
4. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
Ikeda T; Maruyama K; Kaji H; Akagi M
Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
[TBL] [Abstract][Full Text] [Related]
5. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol.
Trabulus S; Altiparmak MR; Apaydin S; Serdengecti K; Sariyar M
Transplant Proc; 2008; 40(1):160-6. PubMed ID: 18261575
[TBL] [Abstract][Full Text] [Related]
6. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
Takata S; Abbaspour A; Yonezu H; Yasui N
J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
[TBL] [Abstract][Full Text] [Related]
7. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2009 Aug; 50(4):474-81. PubMed ID: 19718394
[TBL] [Abstract][Full Text] [Related]
9. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
10. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients.
Tapaninen TS; Venesmaa PK; Jurvelin JS; Miettinen HJ; Kröger HP
Scand J Surg; 2010; 99(1):32-7. PubMed ID: 20501356
[TBL] [Abstract][Full Text] [Related]
11. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study.
Arabmotlagh M; Rittmeister M; Hennigs T
J Orthop Res; 2006 Jul; 24(7):1336-41. PubMed ID: 16705719
[TBL] [Abstract][Full Text] [Related]
12. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
de Nijs RN; Jacobs JW; Lems WF; Laan RF; Algra A; Huisman AM; Buskens E; de Laet CE; Oostveen AC; Geusens PP; Bruyn GA; Dijkmans BA; Bijlsma JW;
N Engl J Med; 2006 Aug; 355(7):675-84. PubMed ID: 16914703
[TBL] [Abstract][Full Text] [Related]
13. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty.
Arabmotlagh M; Pilz M; Warzecha J; Rauschmann M
J Orthop Res; 2009 Feb; 27(2):183-8. PubMed ID: 18752281
[TBL] [Abstract][Full Text] [Related]
14. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty - A randomized Controlled Trial.
Kobayashi N; Inaba Y; Uchiyama M; Ike H; Kubota S; Saito T
J Arthroplasty; 2016 Jan; 31(1):333-8. PubMed ID: 26260784
[TBL] [Abstract][Full Text] [Related]
16. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Watts NB; Becker P
Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
[TBL] [Abstract][Full Text] [Related]
17. Alendronate inhibits periprosthetic bone loss around uncemented femoral components.
Nishioka T; Yagi S; Mitsuhashi T; Miyamoto M; Tamura T; Kobayashi T; Enishi T
J Bone Miner Metab; 2007; 25(3):179-83. PubMed ID: 17447116
[TBL] [Abstract][Full Text] [Related]
18. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
[TBL] [Abstract][Full Text] [Related]
19. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
20. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
